Tandem Diabetes Care Inc (TNDM)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.40B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tandem Diabetes Care Inc (TNDM) Earnings: Report Dates and Results
Tandem Diabetes Care (TNDM) is expected to report earnings on Feb 17, 2027. In the quarter ended Sep 30, 2026, Tandem Diabetes Care reported EPS of -$0.10, above the -$0.27 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TNDM has an expected report date of Feb 17, 2027.
TNDM Earnings Call
The latest TNDM earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, TNDM beat 22, missed 16 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $283.69M, up 13.8% from $249.25M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.10 | -$0.27 | -$0.36 - -$0.16 | +62.96% | Beat | N/A | 20 | 3 up, 12 down | Nov 5, 2026 | $283.69M |
| Jun 30, 2026 | -$0.31 | -$0.34 | -$0.41 - -$0.23 | +8.82% | Beat | N/A | 18 | 1 up, 3 down | Aug 6, 2026 | $254.56M |
| Mar 31, 2026 | -$0.30 | -$0.44 | -$0.54 - -$0.35 | +31.82% | Beat | N/A | 18 | 5 up, 10 down | May 7, 2026 | $247.22M |
| Dec 31, 2025 | -$0.01 | -$0.09 | -$0.40 - $0.03 | +88.89% | Beat | N/A | 21 | 2 up, 1 down | Feb 19, 2026 | $290.38M |
| Sep 30, 2025 | -$0.31 | -$0.34 | -$0.54 - -$0.07 | +8.82% | Beat | N/A | 20 | 3 up, 15 down | Nov 6, 2025 | $249.25M |
| Jun 30, 2025 | -$0.48 | -$0.40 | -$0.57 - -$0.26 | -20.00% | Miss | N/A | 20 | 1 up, 0 down | Aug 6, 2025 | $240.68M |
| Mar 31, 2025 | -$0.67 | -$0.61 | -$0.67 - -$0.49 | -9.84% | Miss | N/A | 20 | 0 up, 1 down | Apr 30, 2025 | $234.42M |
| Dec 31, 2024 | -$0.44 | -$0.24 | -$0.37 - -$0.05 | -84.81% | Miss | N/A | 17 | 2 up, 9 down | Feb 26, 2025 | $282.65M |
| Sep 30, 2024 | -$0.36 | -$0.41 | -$0.50 - -$0.27 | +12.20% | Beat | N/A | 19 | 1 up, 0 down | Nov 6, 2024 | $243.97M |
| Jun 30, 2024 | -$0.48 | -$0.53 | -$0.61 - -$0.35 | +9.43% | Beat | N/A | 11 | 0 up, 0 down | Aug 1, 2024 | $221.91M |
| Mar 31, 2024 | -$0.64 | -$0.76 | -$0.85 - -$0.58 | +15.79% | Beat | N/A | 12 | 0 up, 0 down | May 2, 2024 | $191.67M |
| Dec 31, 2023 | -$0.27 | -$0.25 | -$0.40 - -$0.10 | -8.00% | Miss | N/A | 13 | 0 up, 0 down | Feb 21, 2024 | $196.80M |
| Sep 30, 2023 | -$0.38 | -$0.36 | -$0.59 - $0.02 | -5.56% | Miss | N/A | 14 | 0 up, 0 down | Nov 1, 2023 | $185.62M |
| Jun 30, 2023 | -$0.30 | -$0.49 | -$0.63 - -$0.43 | +38.78% | Beat | N/A | 8 | 0 up, 0 down | Aug 3, 2023 | $195.92M |
| Mar 31, 2023 | -$0.63 | -$0.53 | -$0.69 - -$0.26 | -18.87% | Miss | N/A | 12 | 0 up, 0 down | May 3, 2023 | $169.38M |
| Dec 31, 2022 | -$0.25 | -$0.06 | -$0.22 - $0.07 | -316.67% | Miss | -256.3% | 13 | 0 up, 0 down | Feb 22, 2023 | $220.50M |
| Sep 30, 2022 | -$0.27 | -$0.05 | -$0.18 - $0.06 | -440.00% | Miss | -400.0% | 13 | 0 up, 0 down | Nov 2, 2022 | $204.55M |
| Jun 30, 2022 | -$0.23 | $0.02 | -$0.04 - $0.17 | N/A | N/A | -483.3% | 11 | 0 up, 1 down | Aug 3, 2022 | $200.26M |
| Mar 31, 2022 | -$0.23 | -$0.07 | -$0.23 - $0.17 | -228.57% | Miss | N/A | 11 | 3 up, 0 down | May 4, 2022 | $175.91M |
| Dec 31, 2021 | $0.16 | $0.21 | $0.10 - $0.33 | -23.81% | Miss | -27.3% | 12 | 0 up, 0 down | Feb 22, 2022 | $210.00M |
| Sep 30, 2021 | $0.09 | $0.06 | -$0.02 - $0.18 | +50.00% | Beat | N/A | 15 | N/A | Nov 3, 2021 | $179.63M |
| Jun 30, 2021 | $0.06 | -$0.08 | -$0.28 - $0.03 | +175.00% | Beat | N/A | 15 | N/A | Aug 4, 2021 | $172.14M |
| Mar 31, 2021 | -$0.08 | -$0.15 | -$0.28 - -$0.04 | +46.67% | Beat | N/A | 14 | N/A | May 5, 2021 | $141.04M |
| Dec 31, 2020 | $0.22 | $0.12 | $0.03 - $0.23 | +83.33% | Beat | +450.0% | 14 | N/A | Feb 24, 2021 | $168.06M |
| Sep 30, 2020 | -$0.15 | -$0.12 | -$0.28 - $0.05 | -25.00% | Miss | N/A | 15 | N/A | Nov 5, 2020 | $123.60M |
| Jun 30, 2020 | -$0.45 | -$0.25 | -$0.35 - -$0.09 | -80.00% | Miss | N/A | 14 | N/A | Jul 30, 2020 | $109.24M |
| Mar 31, 2020 | -$0.25 | -$0.18 | -$0.29 - -$0.08 | -38.89% | Miss | N/A | 14 | N/A | Apr 30, 2020 | $97.93M |
| Dec 31, 2019 | $0.04 | -$0.05 | -$0.21 - $0.10 | +180.00% | Beat | +100.0% | 13 | N/A | Feb 24, 2020 | $108.40M |
| Sep 30, 2019 | -$0.09 | -$0.22 | -$0.38 - -$0.13 | +59.09% | Beat | N/A | 12 | N/A | Nov 4, 2019 | $94.66M |
| Jun 30, 2019 | -$0.03 | -$0.29 | -$0.42 - -$0.15 | +89.66% | Beat | N/A | 12 | N/A | Aug 1, 2019 | $93.25M |
| Mar 31, 2019 | -$0.40 | -$0.29 | -$0.41 - -$0.14 | -37.93% | Miss | N/A | 12 | N/A | Apr 30, 2019 | $66.00M |
| Dec 31, 2018 | $0.02 | -$0.20 | -$0.24 - -$0.14 | +110.00% | Beat | N/A | 11 | N/A | Feb 26, 2019 | $76.20M |
| Sep 30, 2018 | -$0.30 | -$0.31 | -$0.46 - -$0.21 | +3.23% | Beat | N/A | 10 | N/A | Nov 1, 2018 | $46.26M |
| Jun 30, 2018 | -$0.33 | -$0.33 | -$0.39 - -$0.31 | 0.00% | In line | N/A | 6 | N/A | Jul 30, 2018 | $34.13M |
| Mar 31, 2018 | -$1.03 | -$0.62 | -$0.74 - -$0.45 | -66.13% | Miss | N/A | 6 | N/A | Apr 26, 2018 | $27.28M |
| Dec 31, 2017 | -$1.22 | -$1.30 | -$1.87 - -$1.02 | +6.15% | Beat | N/A | 5 | N/A | Mar 1, 2018 | $40.29M |
| Sep 30, 2017 | -$3.59 | -$3.74 | N/A | +4.01% | Beat | N/A | N/A | N/A | Oct 26, 2017 | $27.00M |
| Jun 30, 2017 | -$4.40 | -$4.79 | N/A | +8.14% | Beat | N/A | N/A | N/A | Jul 27, 2017 | $21.33M |
| Mar 31, 2017 | -$7.50 | -$6.11 | N/A | -22.75% | Miss | N/A | N/A | N/A | Apr 27, 2017 | $18.98M |
| Dec 31, 2016 | -$5.55 | -$6.49 | N/A | +14.48% | Beat | N/A | N/A | N/A | Mar 8, 2017 | $28.91M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.47, after -$1.92 the year before. It was -$28.05 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.47 | N/A |
| Dec 31, 2024 | -$1.92 | N/A |
| Dec 31, 2023 | -$1.58 | N/A |
| Dec 31, 2022 | -$0.98 | -526.1% |
| Dec 31, 2021 | $0.23 | N/A |
| Dec 31, 2020 | -$0.63 | N/A |
| Dec 31, 2019 | -$0.48 | N/A |
| Dec 31, 2018 | -$1.64 | N/A |
| Dec 31, 2017 | -$16.71 | N/A |
| Dec 31, 2016 | -$28.05 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,200 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,215 | 18 | |
| 2026Q2 | Jun 30, 2026 | 6,709 | 17 | |
| 2026Q1 | Mar 31, 2026 | 8,197 | 24 | |
| 2025Q4 | Dec 31, 2025 | 8,968 | 22 | |
| 2025Q3 | Sep 30, 2025 | 8,293 | 17 | |
| 2025Q2 | Jun 30, 2025 | 8,503 | 19 | |
| 2025Q1 | Mar 31, 2025 | 9,024 | 23 | |
| 2024Q4 | Dec 31, 2024 | 11,242 | 23 |
2026Q3 Earnings Call
Opening remarks
Susan Morrison Executive Vice President and Chief Administrative Officer Hello, and welcome to Tandem's 2026 Third Quarter Earnings Call. Today's discussion will include forward-looking statements, including statements about our CEO transition and its timing, our leadership, strategy, product pipeline, development timelines, financial performance, including profitability and operating plans. These statements speak only as of today's date. They reflect our current expectations about future events and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements, which are described in our press release issued earlier today and under the Risk Factors portion of our most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as the Form 8-K we issued today. Today's discussion will also include references to both GAAP and non-GAAP financial measures. Please refer to our earnings release issued today and available on the Investor Center portion of our website for a reconciliation of non-GAAP measures to their most directly comparable GAAP financial measure and other information regarding our use of non-GAAP financial measures. In addition, we also issued a press release this afternoon on the planned evolution of Tandem's CEO leadership. To speak to this announcement, the Chair of Tandem's Board of Directors, Beckie Robertson, will join us in opening today's call. We'll then move to our third quarter earnings results and company update from John Sheridan, President and CEO, and Leigh Vosseller, Executive Vice President and Chief Financial Officer. After their prepared remarks, we'll open the call for questions with John and Leigh. Thank you in advance for limiting yourself to one question before rejoining the queue. I'll now turn the call over to Beckie.
Rebecca Robertson Chair of the Board of Directors Thanks, Susan, and good afternoon, everyone. Today's succession announcement marks an important milestone for Tandem Diabetes Care. As part of a planned leadership transition, we celebrate John Sheridan's accomplished tenure as he prepares to retire at the end of 2026, and we are thrilled to welcome Jeannette Bankes as Tandem's next President and CEO. On behalf of the Board, I want to thank John for more than a decade of service to Tandem, including eight years as CEO. Under John's leadership, Tandem has grown into a global innovator in diabetes care. He launched Control-IQ, our first hybrid closed-loop technology, advanced our digital health strategy, and expanded our portfolio with the introduction of Mobi. In addition, he established the foundation for Tandem to operate at scale internationally and set in motion business model changes that broaden customer access. Just as important, he cultivated a mission-driven culture that will continue to define this company. With this foundation in place, Jeannette is the right leader to guide Tandem through its next phase of growth.
Frequently Asked Questions About TNDM
When is Tandem Diabetes Care's next earnings date?
Tandem Diabetes Care's next earnings report is expected for Feb 17, 2027.
Did TNDM beat earnings estimates last quarter?
Yes. Tandem Diabetes Care reported EPS of -$0.10 for the quarter ended Sep 30, 2026, above the -$0.27 estimate, a 62.96% surprise.
What EPS do analysts expect from TNDM next quarter?
The consensus EPS estimate for Tandem Diabetes Care for the quarter ending Dec 31, 2026 is $0.10 from 26 analysts, with estimates from -$0.01 to $0.22.
How often does TNDM beat earnings estimates?
Tandem Diabetes Care beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +10.83%.
TNDM pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors